Sunday, March 1, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

New opioids called Nitazenes may be 20 times stronger than Fentanyl

Despite the global COVID-19 pandemic, the opioid epidemic persists and seems to be worsening.

In areas throughout the United States, a highly potent new synthetic opioid is starting to show up on the streets and is having devastating effects on its users. A class of opioids called ‘nitazenes’ has recently been found in syringes examined by scientists throughout the country.

Forensic experts have found that the syringes used in some overdoses contain a potent synthetic opioid class — nitazenes — which is up to 20 times more powerful than fentanyl — a drug that is already 50 times more powerful than heroin and 80 to 100 times more potent than morphine.

Source: Healthline

https://www.healthline.com/health-news/new-opioids-called-nitazenes-may-be-20-times-stronger-than-fentanyl

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!